You are here

Generic Adenoscan (Adenosine Injection) Launched in U.S.

Product is adjunct to myocardial perfusion scintigraphy (September 24)

A generic equivalent to Adenoscan (adenosine injection) has been launched in the U.S. The generic product’s manufacturer (Teva Pharmaceuticals) was the first to file, making the product eligible for 180 days of marketing exclusivity.

Adenoscan is supplied as 20-mL and 30-mL vials and is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.

Marketed by Astellas Pharma, Adenoscan had annual sales of approximately $65 million in the U.S., according to IMS data as of June 30, 2013.

Source: Teva Pharmaceuticals; September 24, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs